ALPHA FETOPROTEIN TUMOR MARKER
- ALPHA FETOPROTEIN TUMOR MARKER
- Start Date
- Expiration Date
- AFP Tumor Marker
- CPT Codes
- Reference Test
- Transport Info
- Fasting Required?
- Patient Instructions
- Reference Range
Male and non-pregnant female: less than or equal to 6.1 ng/mL
Chemiluminescenct Immunoassay (CLIA)
Quantitative measurements used to aid in the management of nonseminomatuous testicular cancer. Diagnosis of hepatocellular carcinoma, and certain germ cell neoplasms of the testis, ovary, retroperitoneum, and mediastinum; differential diagnosis of neonatal hepatitis versus biliary atresia in newborns. AFP is also increased in embryonal carcinoma and endodermal sinus tumor (extremely elevated amounts). High in some cases of massive hepatic necrosis, acute hepatitis, and chronic active hepatitis.
When used as a tumor marker, increased AFP levels have been observed in patients with primary hepatocellular carcinoma, nonseminomatous testicular carcinomas, and ovarian carcinomas, as well as in other epithelial tumors, especially those of the GI tract. AFP is also increased in some nonmalignant hepatic diseases, such as viral hepatitis and active cirrhosis. Levels of less than 200 ng/mL have been reported in these benign diseases. The specificity of AFP for malignancy is greatest at levels greater than 1,000 ng/mL. Smaller (more treatable) tumors will not be detected if this threshold is used, however. For this reason, levels between 15-200 ng/mL should be interpreted with caution.